MultibaggerLab Blog

A practical guide to five-day momentum, relative volume, trend context and risk controls—plus the latest mechanical scanner report.

How to compare category fit, plan type, rolling returns, costs, risk and portfolio overlap without chasing a recent-return table.

A practical framework for resistance, relative volume, close strength and failed-breakout risk—without turning a scan into a stock recommendation.

How to interpret institutional-flow data with market breadth and sector leadership—without turning one daily number into a stock call.

Price-to-earnings in plain English — the formula two ways, trailing vs forward vs index PE, and why "a good PE" only means something relative to growth and peers.

Three ways to measure how well a company turns capital into profit — the formulas, the DuPont catch that lets leverage flatter ROE, and which to trust.

How to read a company's leverage, the companion checks (interest coverage, maturity profile), and when "debt-free" is a strength versus a sign it can't grow.

What promoter holding tells you, where it's disclosed, and why a rising share pledge is one of the most reliable warning signs in Indian small and mid caps.

Minervini's Volatility Contraction Pattern — shrinking pullbacks, a volume dry-up, and the pivot — how to spot it, screen for it, and where the buy point sits.

The three filters that separate real compounders from noise, a copy-paste Screener.in query, and what past 10-baggers looked like before they ran.

The five pillars of a fundamentally strong business — earnings growth, ROCE/ROE, balance sheet, cash conversion, management — with thresholds and a copy-paste screen.

Buying near the high feels wrong, but the 52-week-high effect is one of the most studied momentum anomalies. How it got there matters — and how to screen for it properly.

ROCE is the single most useful quality number for a long-term investor. What it measures, how it differs from ROE, the bands that matter, and where it misleads.

The listed railway universe grouped by what each company actually does — rolling stock, construction, financing, operations — and the order-book story behind the theme.

The listed defence companies by segment — aircraft, electronics, warships, missiles, drones — plus the indigenisation and export drivers, and the valuation risk after the 2023-24 re-rating.

Why the "top 10 for 2026" lists online are mostly marketing — and a step-by-step method to build and track a shortlist of your own instead.

Share price is not opportunity. What actually predicts the small minority of low-priced stocks that compound — and the traps that catch the rest.

QGLP, SMILE and the niche-leader playbook — the repeatable frameworks behind the well-known portfolios, and why cloning holdings blind underperforms.

Clear explanation of what “multibagger” really means, why most 10x stories start small, and the math of compounding over time.

A step‑by‑step checklist to quickly filter out junk and focus on companies where long‑term compounding is at least possible.

The three fundamental filters that separate real compounders from noise, a copy‑paste Screener.in query, and what past 10‑baggers looked like on this screen before they ran.

Not a tip sheet. How to screen for the profile winners start with, track a shortlist through 2026, and read the sector themes with a real multi‑year runway.

Share price is not opportunity. The base rates for sub‑₹100 and sub‑₹10 stocks, what the low‑priced names that did compound had in common, and the traps unique to the category.

A simple framework to think about India, US tech and Bitcoin together when you’re building a long‑term, multi‑engine portfolio.

Practical rules on sizing, diversification and exits so you don’t blow up your capital while chasing 10x ideas.

What actually counts as a small cap on NSE, how to screen for fundamentally strong names, and the traps that catch most first-time investors.

Forget listicles — the five criteria that actually matter, how to weight large, mid and small caps, and what "long term" should really mean.

What a stock screener actually does, the five filters worth building into any screen, and the mistakes that make most screens useless.

The sector-specific checks that matter beyond the usual growth and debt filters, and the risks unique to pharma.

Smallcap mutual funds or picking small cap stocks yourself? A practical comparison of the two approaches and what to check before choosing either.

What sets Indian public sector banks apart from private banks for investors — ownership, asset quality, valuation and the specific checks worth running.

What momentum investing actually is, why it works academically, and the practical risks Indian retail investors need to manage.

Why penny stocks are pitched as the next multibagger, and the liquidity, disclosure and manipulation risks most lists don't mention.

India's semiconductor push is real, but most "semiconductor stocks" today are adjacent plays, not chipmakers. A framework for telling the two apart.

The stocks under the "data center" label span REITs, power, cooling, land and connectivity plays. A framework for screening before you buy the theme.

How private sector banks differ from PSU banks for investors — execution consistency, valuation premium and the checks worth running before you buy.

What real estate investment trusts are, how they work under India's SEBI framework, and how to evaluate one before adding it to a portfolio.